Comparison of BNT162b2 and mRNA1273 vaccines in solid organ transplant recipients: Post‐Hoc analysis of a Japanese national prospective study DOI
Mikiko Yoshikawa, Yoichiro Natori, Rikako Oki

et al.

Scandinavian Journal of Immunology, Journal Year: 2023, Volume and Issue: 98(4)

Published: June 28, 2023

Abstract The coronavirus disease‐19 (COVID‐19) vaccine efficacy and immunogenicity in the immunocompetent population are well established. However, solid organ transplant (SOT) recipients, because of their use immunosuppressive medication, these severe acute respiratory syndrome 2 (SARS‐CoV‐2) vaccines remains suboptimal. Both BNT162b2 mRNA1273 have been used for some time, but has not directly compared this immunocompromised patient group. We performed a post‐hoc analysis previous prospective cohort study. inclusion criteria were adult SOT recipients with active grafts at least 1 month after SOT. After giving consent, participants chose to receive either or vaccine. Anti‐spike‐protein‐S antibody against SARS‐CoV‐2 was measured. Propensity scores calculated via logistic regression transform probability having received vaccine, model developed. enrolled 623 recipients. In propensity score‐matched analysis, 100 selected mRNA1273. anti‐spike protein positivity versus 3 weeks first dose, second months 6 dose 10% 19% ( P = .07), 51% 58% .30), 74% 88% .01), 78% 87% .13), respectively. conducted comparison as primary series COVID‐19 found significantly better than BNT162b2.

Language: Английский

Vaccination Strategies: Mixing Paths Versus Matching Tracks DOI Creative Commons

Achilleas Livieratos,

Charalambos Gogos,

Ιάσων Θωμάς

et al.

Vaccines, Journal Year: 2025, Volume and Issue: 13(3), P. 308 - 308

Published: March 13, 2025

Vaccination strategies play a pivotal role in achieving broad and robust immune protection. With the advent of new technologies challenges posed by emerging infectious diseases such as SARS-CoV-2, evaluating efficacy homologous (matching tracks) heterologous (mixing paths) vaccination regimens is critical. This article explores mechanistic insights empirical evidence on benefits limitations these approaches.

Language: Английский

Citations

0
Effectiveness of heterologous and homologous COVID-19 vaccination among immunocompromised individuals: a systematic literature review and meta-analysis DOI Creative Commons
Isabele Pardo,

Aline Miho Maezato,

Gustavo Yano Callado

et al.

Antimicrobial Stewardship & Healthcare Epidemiology, Journal Year: 2024, Volume and Issue: 4(1)

Published: Jan. 1, 2024

Abstract Objectives: We assessed the effectiveness of heterologous vaccination strategy in immunocompromised individuals regarding COVID-19 outcomes, comparing it to homologous approaches. Design: Systematic literature review/meta-analysis. Methods: searched PubMed, CINAHL, EMBASE, Cochrane Central Register Controlled Trials, Scopus, and Web Science from January 1, 2020 September 29, 2023. included studies that evaluated on through outcomes related (levels anti-SARS-CoV-2 spike protein IgG, neutralizing antibodies, symptomatic infection, hospitalization, death) comparison schemes. also used random-effect models produce pooled odds ratio estimates. Heterogeneity was investigated with I 2 estimation. Results: Eighteen met inclusion criteria for this systematic review. Fourteen them provided quantitative data meta-analysis vaccine response, being four meta-analysis. The strategies (heterologous vs homologous) showed no difference developing IgG (odds 1.12 [95% Cl: 0.73–1.72]). Heterologous schemes production antibodies 1.48 0.72–3.05]) nor 1.52 CI: 0.66–3.53]). Conclusions: Alternative vaccinations have shown equivalent antibody response rates schemes, potentially aiding global disparity distribution.

Language: Английский

Citations

2
Homologous versus Heterologous prime-boost COVID-19 Vaccination in autologous hematopoietic stem cell transplantation recipients: a blinded randomized controlled trial DOI Creative Commons
Leyla Sharifi Aliabadi, Manoochehr Karami, Maryam Barkhordar

et al.

Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14

Published: Aug. 1, 2023

Optimizing vaccine efficacy is of particular concern in patients undergoing hematopoietic stem cell transplantation (HSCT), which mainly have an inadequate immune response to primary SARS-CoV-2 vaccination. This investigation aimed explore the potential prime-boost COVID-19 vaccination strategies following autologous (auto-) HSCT.In a randomized clinical trial, who had already received two doses receptor-binding domain (RBD) tetanus toxoid (TT) conjugated during three nine months after auto-HSCT were receive either homologous RBD-TT or heterologous inactivated booster dose four weeks course. The outcome was comparing anti-S IgG Immune status ratio (ISR) versus dose. assessment safety and reactogenicity adverse events considered as secondary outcome.Sixty-one recipients recruited randomly assigned mean ISR 3.40 (95% CI: 2.63- 4.16) before with 90.0% seropositive rate. raised 5.12 4.15- 6.08) 100% rate (P= 0.0064) 3.42 2.67- 4.17) 93.0% seropositivity 0.96). In addition, group suffered more AEs dosage than group, but this difference not statistically significant (p = 0.955). multivariable analysis, strategy (heterologous homologous), level dose, length time between positive predictors serologic No serious event attributed vaccination.In primed first year auto-HSCT, platform resulted considerably enhanced non-significantly higher strategy.

Language: Английский

Citations

4
Case Report: Kinetics and durability of humoral and cellular response of SARS-CoV-2 messenger RNA vaccine in a lung and kidney transplant recipient DOI Creative Commons
James P. Long, Mithil Soni, Pawel Muranski

et al.

Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14

Published: July 3, 2023

We present a case report of 63-year-old female health care worker who is 15 years status post double lung transplant and six living related donor kidney healthy on chronic immunosuppression regimen including prednisone, mycophenolate, tacrolimus received the SARS-CoV-2 mRNA vaccine (Pfizer-BioNTech BNT162b2) primary series had poor initial humoral response to COVID-19 vaccine, then demonstrated robust, sustained immune against S1 S2 antigens for over seven months after receiving recommended doses, booster dose, without developing or other serious adverse events. Her vaccination indicates effective formation anti-spike T cell memory despite immunosuppression. This provides comprehensive characterization her this series. As effectiveness data updated, as better understanding hybrid immunity emerges, these findings may reassure that recipients SOTs be capable durable responses emerging variants SARS-CoV-2.

Language: Английский

Citations

1
Comparison of BNT162b2 and mRNA1273 vaccines in solid organ transplant recipients: Post‐Hoc analysis of a Japanese national prospective study DOI
Mikiko Yoshikawa, Yoichiro Natori, Rikako Oki

et al.

Scandinavian Journal of Immunology, Journal Year: 2023, Volume and Issue: 98(4)

Published: June 28, 2023

Abstract The coronavirus disease‐19 (COVID‐19) vaccine efficacy and immunogenicity in the immunocompetent population are well established. However, solid organ transplant (SOT) recipients, because of their use immunosuppressive medication, these severe acute respiratory syndrome 2 (SARS‐CoV‐2) vaccines remains suboptimal. Both BNT162b2 mRNA1273 have been used for some time, but has not directly compared this immunocompromised patient group. We performed a post‐hoc analysis previous prospective cohort study. inclusion criteria were adult SOT recipients with active grafts at least 1 month after SOT. After giving consent, participants chose to receive either or vaccine. Anti‐spike‐protein‐S antibody against SARS‐CoV‐2 was measured. Propensity scores calculated via logistic regression transform probability having received vaccine, model developed. enrolled 623 recipients. In propensity score‐matched analysis, 100 selected mRNA1273. anti‐spike protein positivity versus 3 weeks first dose, second months 6 dose 10% 19% ( P = .07), 51% 58% .30), 74% 88% .01), 78% 87% .13), respectively. conducted comparison as primary series COVID‐19 found significantly better than BNT162b2.

Language: Английский

Citations

0